VRd
Checked 2026-09-09
Newly diagnosed myeloma (with daratumumab as D-VRd in transplant-eligible patients)
One cycle
every 21 days × 8 · about 24 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Bortezomib Proteasome inhibitor | 1.3 mg/m² | SC | D1, 4, 8, 11 | |
Lenalidomide Immunomodulatory drug (cereblon E3 ligase modulator) | 25 mg once daily | Oral | D1-14 | |
Dexamethasone | 20 mg | Oral | D1, 2, 4, 5, 8, 9, 11, 12 |
Cycles
8 (SWOG S0777); 4-6 before transplant
21-day cycle
Emetogenicity
Minimal (<10%)
G-CSF
Not routine
Notes
- Weekly bortezomib (VRd-lite, 35-day cycles) is standard for frail patients.
- Thromboprophylaxis with lenalidomide-dexamethasone; herpes zoster prophylaxis with bortezomib.
Used in
Products
Source
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.
Other regimens for these cancers
Pegylated liposomal doxorubicin
Platinum-resistant or partially platinum-sensitive ovarian cancer; Kaposi sarcoma
every 28 days
D-VRd (PERSEUS)
Newly diagnosed transplant-eligible myeloma: 4 induction cycles, ASCT, 2 consolidation cycles, then D-R maintenance
every 28 days × 4
DRd (daratumumab + lenalidomide + dexamethasone)
Newly diagnosed transplant-ineligible myeloma (MAIA); relapsed myeloma (POLLUX)
every 28 days
High-dose melphalan and autologous stem-cell transplant
Transplant-eligible myeloma after induction
single day × 1
Lenalidomide maintenance
After autologous transplant
every 28 days
Teclistamab
Relapsed or refractory myeloma after 3 or more lines including a PI, IMiD and CD38 antibody
weekly